Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesFlibanserin demonstrates efficacy and tolerability in pivotal Phase III Trials in pre-menopausal women with Hypoactive Sexual Desire Disorder
Boehringer Ingelheim, 11/17/09
Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number of Satisfying Sexual Events and sexual desire while significantly decreasing the distress associated with Hypoactive Sexual Desire Disorder.1 Flibanserin is an investigational compound that is being developed by Boehringer Ingelheim for the treatment of pre–menopausal women with HSDD.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
AstraZeneca, 03/10/10
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
Bristol Myers-Squibb Company, 03/10/10
Gynecologic Oncology Group Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority
Cell Therapeutics, 03/08/10
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
AstraZeneca, 03/10/10
Gynecologic Oncology Group Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority
Cell Therapeutics, 03/08/10
Gynecologic Oncology Group Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority
Cell Therapeutics, 03/05/10
Article Search
Sponsor
Sponsor